Imatinib mesylate (IM) represents the first-line treatment for chronic myeloid leukemia (CML). We hereby relate 3 cases of an IM-induced pityriasis rosea (PR)-like cutaneous eruption. Patients developed an erythematous, slightly pruritic, macular skin eruption, with many lesions having a peripheral collarette of desquamation, confined to the trunk, limbs, and arms with a vaguely dermatomal diffusion. The histologic findings suggested a reactive process to the drug. Full dermatological recovery was obtained after IM discontinuation, but lesions reappeared upon restoring therapy, suggesting the drug-related nature of the rash. To our knowledge this is the first reported PR-like cutaneous eruption to IM.
Pityriasis roseaelike eruption during treatment with imatinib mesylate: Description of 3 cases / V. Brazzelli, F. Prestinari, E. Roveda, T. Barbagallo, E. Bellani, C. Vassallo, E. Orlandi, F. Passamonti, G. Borroni. - In: JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. - ISSN 0190-9622. - 53:5 suppl. 1(2005), pp. S240-S243. [10.1016/j.jaad.2004.10.888]
Pityriasis roseaelike eruption during treatment with imatinib mesylate: Description of 3 cases
F. PassamontiPenultimo
;
2005
Abstract
Imatinib mesylate (IM) represents the first-line treatment for chronic myeloid leukemia (CML). We hereby relate 3 cases of an IM-induced pityriasis rosea (PR)-like cutaneous eruption. Patients developed an erythematous, slightly pruritic, macular skin eruption, with many lesions having a peripheral collarette of desquamation, confined to the trunk, limbs, and arms with a vaguely dermatomal diffusion. The histologic findings suggested a reactive process to the drug. Full dermatological recovery was obtained after IM discontinuation, but lesions reappeared upon restoring therapy, suggesting the drug-related nature of the rash. To our knowledge this is the first reported PR-like cutaneous eruption to IM.File | Dimensione | Formato | |
---|---|---|---|
1-s2.0-S0190962205010285-main.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
273.36 kB
Formato
Adobe PDF
|
273.36 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.